{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:53:31Z","timestamp":1791003211557,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,4,4]],"date-time":"2017-04-04T00:00:00Z","timestamp":1491264000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s40263-017-0417-0","type":"journal-article","created":{"date-parts":[[2017,4,4]],"date-time":"2017-04-04T19:24:23Z","timestamp":1491333863000},"page":"421-432","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD)"],"prefix":"10.1007","volume":"31","author":[{"given":"Katelyn R.","family":"Keyloun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan N.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Hepp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Gillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Thase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily Beth","family":"Devine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,4]]},"reference":[{"issue":"1","key":"417_CR1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/mpr.138","volume":"12","author":"L Andrade","year":"2003","unstructured":"Andrade L, Caraveo-Anduaga JJ, Berglund P, Bijl RV, De Graaf R, Vollebergh W, et al. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiatr Res. 2003;12(1):3\u201321.","journal-title":"Int J Methods Psychiatr Res"},{"issue":"12","key":"417_CR2","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1176\/ajp.2006.163.12.2141","volume":"163","author":"WM Compton","year":"2006","unstructured":"Compton WM, Conway KP, Stinson FS, Grant BF. Changes in the prevalence of major depression and comorbid substance use disorders in the United States between 1991\u20131992 and 2001\u20132002. Am J Psychiatry. 2006;163(12):2141\u20137.","journal-title":"Am J Psychiatry"},{"key":"417_CR3","unstructured":"Substance Abuse and Mental Health Services Administration. Results from the 2013 National Survey on Drug Use and Health: Mental Health Findings. 2014. http:\/\/www.samhsa.gov\/data\/sites\/default\/files\/NSDUHmhfr2013\/NSDUHmhfr2013.pdf . Accessed 7 July 2016."},{"issue":"12","key":"417_CR4","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.4088\/JCP.v64n1211","volume":"64","author":"PE Greenberg","year":"2003","unstructured":"Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003;64(12):1465\u201375.","journal-title":"J Clin Psychiatry"},{"key":"417_CR5","unstructured":"American Psychiatric Association (APA). Practice guidelines for the treatment of patients with major depressive disorder, 3rd edition. Arlington, VA: APA; 2010. http:\/\/psychiatryonline.org\/guidelines . Accessed 7 July 2016."},{"issue":"12","key":"417_CR6","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archpsyc.55.12.1128","volume":"55","author":"CA Melfi","year":"1998","unstructured":"Melfi CA, Chawla AJ, Croghan TW, Hanna MP, Kennedy S, Sredl K. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry. 1998;55(12):1128\u201332.","journal-title":"Arch Gen Psychiatry"},{"issue":"12","key":"417_CR7","first-page":"1327","volume":"6","author":"N Sood","year":"2000","unstructured":"Sood N, Treglia M, Obenchain RL, Dulisse B, Melfi CA, Croghan TW. Determinants of antidepressant treatment outcome. Am J Manag Care. 2000;6(12):1327\u201336.","journal-title":"Am J Manag Care"},{"key":"417_CR8","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1192\/bjp.179.42.s4","volume":"42","author":"RM Hirschfeld","year":"2001","unstructured":"Hirschfeld RM. Clinical importance of long-term antidepressant treatment. Br J Psychiatry Suppl. 2001;42:S4\u20138.","journal-title":"Br J Psychiatry Suppl"},{"issue":"2","key":"417_CR9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/01.yic.0000199452.16682.b8","volume":"21","author":"AC Akerblad","year":"2006","unstructured":"Akerblad AC, Bengtsson F, von Knorring L, Ekselius L. Response, remission and relapse in relation to adherence in primary care treatment of depression: a 2-year outcome study. Int Clin Psychopharmacol. 2006;21(2):117\u201324.","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"417_CR10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44\u20137.","journal-title":"Value Health"},{"issue":"21","key":"417_CR11","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/archinte.165.21.2497","volume":"165","author":"W Katon","year":"2005","unstructured":"Katon W, Cantrell CR, Sokol MC, Chiao E, Gdovin JM. Impact of antidepressant drug adherence on comorbid medication use and resource utilization. Arch Intern Med. 2005;165(21):2497\u2013503.","journal-title":"Arch Intern Med"},{"issue":"4","key":"417_CR12","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/01.mlr.0000204287.82701.9b","volume":"44","author":"CR Cantrell","year":"2006","unstructured":"Cantrell CR, Eaddy MT, Shah MB, Regan TS, Sokol MC. Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Med Care. 2006;44(4):300\u20133.","journal-title":"Med Care"},{"issue":"5","key":"417_CR13","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.4088\/JCP.14m09531","volume":"77","author":"A Krivoy","year":"2016","unstructured":"Krivoy A, Balicer RD, Feldman B, Hoshen M, Zalsman G, Weizman A, et al. Adherence to antidepressants is associated with lower mortality: a 4-year population-based cohort study. J Clin Psychiatry. 2016;77(5):e566\u201372.","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"417_CR14","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2165\/00023210-200822110-00005","volume":"22","author":"DV Sheehan","year":"2008","unstructured":"Sheehan DV, Keene MS, Eaddy M, Krulewicz S, Kraus JE, Carpenter DJ. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and\/or anxiety disorders. CNS Drug. 2008;22(11):963\u201373.","journal-title":"CNS Drug"},{"key":"417_CR15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1471-244X-10-64","volume":"10","author":"B Prukkanone","year":"2010","unstructured":"Prukkanone B, Vos T, Burgess P, Chaiyakunapruk N, Bertram M. Adherence to antidepressant therapy for major depressive patients in a psychiatric hospital in Thailand. BMC Psychiatry. 2010;10:64.","journal-title":"BMC Psychiatry"},{"issue":"6","key":"417_CR16","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/da.21952","volume":"29","author":"CH Wu","year":"2012","unstructured":"Wu CH, Farley JF, Gaynes BN. The association between antidepressant dosage titration and medication adherence among patients with depression. Depress Anxiety. 2012;29(6):506\u201314.","journal-title":"Depress Anxiety"},{"key":"417_CR17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1471-244X-9-38","volume":"9","author":"N Sawada","year":"2009","unstructured":"Sawada N, Uchida H, Suzuki T, Watanabe K, Kikuchi T, Handa T, et al. Persistence and compliance to antidepressant treatment in patients with depression: a chart review. BMC Psychiatry. 2009;9:38.","journal-title":"BMC Psychiatry"},{"key":"417_CR18","unstructured":"National Committee for Quality Assurance (NCQA). The State of Health Care Quality Report 2014. 2014. http:\/\/store.ncqa.org\/index.php\/2014-state-of-health-care-quality-report.html . Account required. Accessed 7 July 2016."},{"key":"417_CR19","unstructured":"Application: Specimen or Data Use, Non-Identifiable (and self-determination) version 5.70. UW Human Subjects Division. 2016. http:\/\/www.washington.edu\/research\/hsd\/docs\/295 . Accessed 7 July 2016."},{"key":"417_CR20","unstructured":"Truven Health Analytics MarketScan Database: Better Understand Health Economics and Treatment Outcomes. 2016. http:\/\/truvenhealth.com\/your-healthcare-focus\/life-sciences\/data-databases-and-online-tools . Accessed 7 July 2016."},{"issue":"5","key":"417_CR21","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1176\/ps.2009.60.5.617","volume":"60","author":"SC Marcus","year":"2009","unstructured":"Marcus SC, Hassan M, Olfson M. Antidepressant switching among adherent patients treated for depression. Psychiatr Serv. 2009;60(5):617\u201323.","journal-title":"Psychiatr Serv"},{"issue":"1","key":"417_CR22","doi-asserted-by":"crossref","first-page":"76","DOI":"10.18553\/jmcp.2014.20.1.76","volume":"20","author":"RL Wade","year":"2014","unstructured":"Wade RL, Kindermann SL, Hou Q, Thase ME. Comparative assessment of adherence measures and resource use in SSRI\/SNRI-treated patients with depression using second-generation antipsychotics or L-methylfolate as adjunctive therapy. J Manag Care Pharm. 2014;20(1):76\u201385.","journal-title":"J Manag Care Pharm"},{"key":"417_CR23","unstructured":"USP Medicare Model Guidelines v6.0. 2014. http:\/\/www.usp.org\/sites\/default\/files\/usp_pdf\/EN\/uspmmg_v6_0_w_exampledrugs_rev140415.pdf . Accessed 20 January 2017."},{"key":"417_CR24","unstructured":"National Committee for Quality Assurance (NCQA). HEDIS 2015: healthcare effectiveness data and information set. 2014; 1 & 2. http:\/\/www.ncqa.org\/Portals\/0\/HEDISQM\/Hedis2015\/List_of_HEDIS_2015_Measures.pdf . Accessed 7 July 2016."},{"issue":"3","key":"417_CR25","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/YIC.0b013e328343ba1e","volume":"26","author":"X Liu","year":"2011","unstructured":"Liu X, Tepper PG, Able SL. Adherence and persistence with duloxetine and hospital utilization in patients with major depressive disorder. Int Clin Psychopharmacol. 2011;26(3):173\u201380.","journal-title":"Int Clin Psychopharmacol"},{"issue":"7","key":"417_CR26","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1185\/03007995.2011.576663","volume":"27","author":"J Wang","year":"2011","unstructured":"Wang J, Liu X, Mullins CD. Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases. Curr Med Res Opin. 2011;27(7):1303\u201313.","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"417_CR27","doi-asserted-by":"crossref","first-page":"725","DOI":"10.7326\/0003-4819-149-10-200811180-00007","volume":"149","author":"A Qaseem","year":"2008","unstructured":"Qaseem A, Snow V, Denberg TD, Forciea MA, Owens DK. Clinical Efficacy Assessment Subcommittee of American College of P. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;149(10):725\u201333.","journal-title":"Ann Intern Med"},{"key":"417_CR28","unstructured":"Chu L-H, Kawatkar A, Gu A. A SAS\u00ae macro program to calculate medication adherence rate for single and multiple medication use. Kaiser Permanente. 2002. http:\/\/www.wuss.org\/proceedings11\/Papers_Chu_L_74886.pdf . Accessed 7 July 2016."},{"issue":"7\u20138","key":"417_CR29","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1345\/aph.1H018","volume":"40","author":"LM Hess","year":"2006","unstructured":"Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40(7\u20138):1280\u20138.","journal-title":"Ann Pharmacother"},{"key":"417_CR30","unstructured":"Nau DP. Proportion of days covered (PDC) as a preferred method of measuring medication adherence. Pharm. Qual. Alliance. 2009. http:\/\/ep.yimg.com\/ty\/cdn\/epill\/pdcmpr.pdf . Accessed 7 July 2016."},{"issue":"9","key":"417_CR31","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1185\/03007990903126833","volume":"25","author":"S Karve","year":"2009","unstructured":"Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009;25(9):2303\u201310.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"417_CR32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11020-005-3781-1","volume":"7","author":"K Rost","year":"2005","unstructured":"Rost K, Dickinson LM, Fortney J, Westfall J, Hermann RC. Clinical improvement associated with conformance to HEDIS-based depression care. Ment Health Serv Res. 2005;7(2):103\u201312.","journal-title":"Ment Health Serv Res"},{"issue":"1","key":"417_CR33","doi-asserted-by":"crossref","first-page":"43","DOI":"10.18553\/jmcp.2006.12.1.43","volume":"12","author":"RL Robinson","year":"2006","unstructured":"Robinson RL, Long SR, Chang S, Able S, Baser O, Obenchain RL, et al. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims. J Manag Care Pharm. 2006;12(1):43\u201354.","journal-title":"J Manag Care Pharm"},{"issue":"6","key":"417_CR34","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"RA Deyo","year":"1992","unstructured":"Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"417_CR35","first-page":"381","volume":"3","author":"H Nersesyan","year":"2007","unstructured":"Nersesyan H, Slavin KV. Current aproach to cancer pain management: availability and implications of different treatment options. Ther Clin Risk Manag. 2007;3(3):381\u2013400.","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"417_CR36","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3111\/13696998.2011.594347","volume":"14","author":"M Gore","year":"2011","unstructured":"Gore M, Tai KS, Sadosky A, Leslie D, Stacey BR. Clinical comorbidities, treatment patterns, and direct medical costs of patients with osteoarthritis in usual care: a retrospective claims database analysis. J Med Econ. 2011;14(4):497\u2013507.","journal-title":"J Med Econ"},{"issue":"5","key":"417_CR37","first-page":"455-66b","volume":"20","author":"CM Kozma","year":"2014","unstructured":"Kozma CM, Provenzano DA, Slaton TL, Patel AA, Benson CJ. Complexity of pain management among patients with nociceptive or neuropathic neck, back, or osteoarthritis diagnoses. J Manag Care Spec Pharm. 2014;20(5):455-66b.","journal-title":"J Manag Care Spec Pharm"},{"key":"417_CR38","unstructured":"StataCorp. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP; 2013."},{"key":"417_CR39","unstructured":"Takeda Pharmaceuticals. Trintellix (vortioxetine) tablets, for oral use [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals; 2017. http:\/\/general.takedapharm.com\/content\/file.aspx?filetypecode=TRINTELLIXPI&cacheRandomizer=f5d577cd-6fb4-4d3c-8a8d-f03843449fcb . Accessed 22 Mar 2017."},{"key":"417_CR40","unstructured":"Forest Pharmaceuticals. Fetzima\u00ae (levomilnacipran) extended-release capsules, for oral use [prescribing information]. Irvine, CA: Allergan; 2014. http:\/\/www.allergan.com\/assets\/pdf\/fetzima_pi#page=1 . Accessed 7 July 2016."},{"issue":"4","key":"417_CR41","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.eurpsy.2009.07.012","volume":"25","author":"MC Serna","year":"2010","unstructured":"Serna MC, Cruz I, Real J, Gasco E, Galvan L. Duration and adherence of antidepressant treatment (2003\u20132007) based on prescription database. Eur Psychiatry. 2010;25(4):206\u201313.","journal-title":"Eur Psychiatry"},{"issue":"2","key":"417_CR42","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3111\/13696990903093537","volume":"12","author":"EQ Wu","year":"2009","unstructured":"Wu EQ, Greenberg PE, Yang E, Yu AP, Ben-Hamadi R, Erder MH. Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI\/SNRIs. J Med Econ. 2009;12(2):124\u201335.","journal-title":"J Med Econ"},{"issue":"4","key":"417_CR43","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1592\/phco.28.4.437","volume":"28","author":"BA Briesacher","year":"2008","unstructured":"Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy. 2008;28(4):437\u201343.","journal-title":"Pharmacotherapy"},{"issue":"9","key":"417_CR44","doi-asserted-by":"crossref","first-page":"728","DOI":"10.18553\/jmcp.2009.15.9.728","volume":"15","author":"J Yeaw","year":"2009","unstructured":"Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9):728\u201340.","journal-title":"J Manag Care Pharm"},{"issue":"9","key":"417_CR45","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1017\/S1092852900019726","volume":"10","author":"SM Stahl","year":"2005","unstructured":"Stahl SM, Grady MM, Moret C, Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 2005;10(9):732\u201347.","journal-title":"CNS Spectr"}],"updated-by":[{"DOI":"10.1007\/s40263-017-0435-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T00:00:00Z","timestamp":1493251200000}}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-017-0417-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-017-0417-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-017-0417-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T01:56:22Z","timestamp":1658886982000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-017-0417-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,4]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["417"],"URL":"https:\/\/doi.org\/10.1007\/s40263-017-0417-0","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,4]]}}}